US Patent

US8492441 — Dosage regimen of an S1P receptor agonist

Method of Use · Assigned to Novartis AG · Expires 2030-11-30 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a dosage regimen for an S1P receptor agonist, where the initial daily dosage is lower than the standard daily dosage.

USPTO Abstract

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Drugs covered by this patent

Mayzent (SIPONIMOD) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2511`	—	Mayzent
`U-2511`	—	Mayzent
`U-2511`	—	Mayzent

Patent Metadata

Patent number: US8492441
Jurisdiction: US
Classification: Method of Use
Expires: 2030-11-30
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.